Cargando…

The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression

Hepatocellular carcinoma is a highly deadly malignancy, accounting for approximately 800,000 deaths worldwide every year. Mutation of the p53 tumor suppressor gene is a common genetic change in HCC, present in 30% of cases. p53(R175H) (corresponding to p53(R172H) in mice) is a hotspot for mutation t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahronian, Leanne G., Driscoll, David R., Klimstra, David S., Lewis, Brian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401698/
https://www.ncbi.nlm.nih.gov/pubmed/25885474
http://dx.doi.org/10.1371/journal.pone.0123816
_version_ 1782367175883882496
author Ahronian, Leanne G.
Driscoll, David R.
Klimstra, David S.
Lewis, Brian C.
author_facet Ahronian, Leanne G.
Driscoll, David R.
Klimstra, David S.
Lewis, Brian C.
author_sort Ahronian, Leanne G.
collection PubMed
description Hepatocellular carcinoma is a highly deadly malignancy, accounting for approximately 800,000 deaths worldwide every year. Mutation of the p53 tumor suppressor gene is a common genetic change in HCC, present in 30% of cases. p53(R175H) (corresponding to p53(R172H) in mice) is a hotspot for mutation that demonstrates “prometastatic” gain-of-function in other cancer models. Since the frequency of p53 mutation increases with tumor grade in HCC, we hypothesized that p53(R172H) is a gain-of-function mutation in HCC that contributes to a decrease in tumor-free survival and an increase in metastasis. In an HCC mouse model, we found that p53(R172H/flox) mice do not have decreased survival, increased tumor incidence, or increased metastasis, relative to p53(flox/flox) littermates. Analysis of cell lines derived from both genotypes indicated that there are no differences in anchorage-independent growth and cell migration. However, shRNA-mediated knockdown of mutant p53 in p53(R172H)-expressing HCC cell lines resulted in decreased cell migration and anchorage-independent growth. Thus, although p53 mutant-expressing cells and tumors do not have enhanced properties relative to their p53 null counterparts, p53(R172H)-expressing HCC cells depend on this mutant for their transformation. p53 mutants have been previously shown to bind and inhibit the p53 family proteins p63 and p73. Interestingly, we find that the levels of p63 and p73 target genes are similar in p53 mutant and p53 null HCC cells. These data suggest that pathways regulated by these p53 family members are similarly impacted by p53(R172H) in mutant expressing cells, and by alternate mechanisms in p53 null cells, resulting in equivalent phenotypes. Consistent with this, we find that p53 null HCC cell lines display lower levels of the TA isoforms of p63 and p73 and higher levels of ΔNp63. Taken together these data point to the importance of p63 and p73 in constraining HCC progression.
format Online
Article
Text
id pubmed-4401698
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44016982015-04-21 The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression Ahronian, Leanne G. Driscoll, David R. Klimstra, David S. Lewis, Brian C. PLoS One Research Article Hepatocellular carcinoma is a highly deadly malignancy, accounting for approximately 800,000 deaths worldwide every year. Mutation of the p53 tumor suppressor gene is a common genetic change in HCC, present in 30% of cases. p53(R175H) (corresponding to p53(R172H) in mice) is a hotspot for mutation that demonstrates “prometastatic” gain-of-function in other cancer models. Since the frequency of p53 mutation increases with tumor grade in HCC, we hypothesized that p53(R172H) is a gain-of-function mutation in HCC that contributes to a decrease in tumor-free survival and an increase in metastasis. In an HCC mouse model, we found that p53(R172H/flox) mice do not have decreased survival, increased tumor incidence, or increased metastasis, relative to p53(flox/flox) littermates. Analysis of cell lines derived from both genotypes indicated that there are no differences in anchorage-independent growth and cell migration. However, shRNA-mediated knockdown of mutant p53 in p53(R172H)-expressing HCC cell lines resulted in decreased cell migration and anchorage-independent growth. Thus, although p53 mutant-expressing cells and tumors do not have enhanced properties relative to their p53 null counterparts, p53(R172H)-expressing HCC cells depend on this mutant for their transformation. p53 mutants have been previously shown to bind and inhibit the p53 family proteins p63 and p73. Interestingly, we find that the levels of p63 and p73 target genes are similar in p53 mutant and p53 null HCC cells. These data suggest that pathways regulated by these p53 family members are similarly impacted by p53(R172H) in mutant expressing cells, and by alternate mechanisms in p53 null cells, resulting in equivalent phenotypes. Consistent with this, we find that p53 null HCC cell lines display lower levels of the TA isoforms of p63 and p73 and higher levels of ΔNp63. Taken together these data point to the importance of p63 and p73 in constraining HCC progression. Public Library of Science 2015-04-17 /pmc/articles/PMC4401698/ /pubmed/25885474 http://dx.doi.org/10.1371/journal.pone.0123816 Text en © 2015 Ahronian et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ahronian, Leanne G.
Driscoll, David R.
Klimstra, David S.
Lewis, Brian C.
The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
title The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
title_full The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
title_fullStr The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
title_full_unstemmed The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
title_short The p53(R172H) Mutant Does Not Enhance Hepatocellular Carcinoma Development and Progression
title_sort p53(r172h) mutant does not enhance hepatocellular carcinoma development and progression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401698/
https://www.ncbi.nlm.nih.gov/pubmed/25885474
http://dx.doi.org/10.1371/journal.pone.0123816
work_keys_str_mv AT ahronianleanneg thep53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression
AT driscolldavidr thep53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression
AT klimstradavids thep53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression
AT lewisbrianc thep53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression
AT ahronianleanneg p53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression
AT driscolldavidr p53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression
AT klimstradavids p53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression
AT lewisbrianc p53r172hmutantdoesnotenhancehepatocellularcarcinomadevelopmentandprogression